CRISPR Therapeutics (CRSP) investor relations material

Strategic priorities and resource allocation

• Six maturing assets will have data readouts in the next 12–18 months, spanning cardiovascular, autoimmune, and rare diseases.

• CASGEVY spending is expected to decrease over time as profitability is reached, with resources shifting to pipeline assets and preclinical programs.

• Portfolio approach enables operational efficiencies and flexible resource allocation as programs advance.

CASGEVY launch and commercial momentum

• Patient initiation for CASGEVY has grown from 100 in 2024 to over 500 in the latest update, indicating exponential momentum.

• Revenue recognition lags patient initiation by two to three quarters due to manufacturing and infusion timelines.

• Pediatric label expansion and reimbursement agreements, such as in Germany, are expected to further accelerate uptake.

• No significant headwinds identified; positive operational execution and growing awareness among patients and physicians.

Pipeline highlights and development plans

• CTX310 (ANGPTL3) demonstrated safe, durable LDL and triglyceride reduction; regulatory guidance will determine phase III path.

• CTX340 targets hypertension with consistent blood pressure reduction; gene editing offers advantages over siRNA therapies.

• Zugo-cel, an allogeneic CAR T, shows high CR rates in oncology and is expanding into multiple autoimmune indications.

• Neuroimmune trials initiated, with evidence of CNS penetration, broadening potential indications.